Psychedelic Drugs Market to Surpass USD 10.3 Billion by 2034

Pune, India, November 7, 2025 - The Global Psychedelic Drugs Market is projected to grow from USD 4.1 billion in 2024 to approximately USD 10.3 billion by 2034, at a CAGR of 9.7%, according to Exactitude Consultancy. The revival of clinical research into psychedelic compounds such as psilocybin, LSD, ketamine, and MDMA-supported by evolving mental-health frameworks-is creating a rapidly maturing therapeutic category.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/48114

Key Takeaways
• Market Size (2024): USD 4.1 Billion
• Forecast (2034): USD 10.3 Billion
• CAGR (2025-2034): 9.7%
• Key Segments: Drug Type, Application, End User, and Region
• Leading Companies: COMPASS Pathways plc, MindMed Inc., Cybin Inc., Atai Life Sciences, Janssen Pharmaceuticals (Johnson & Johnson), MAPS PBC, GH Research, and Small Pharma Ltd.

Market Story
Once stigmatized, psychedelic compounds are now at the forefront of next-generation psychiatry. Clinical studies demonstrate remarkable efficacy of psilocybin and MDMA-assisted therapies in treatment-resistant depression, PTSD, and substance-use disorders. Meanwhile, ketamine clinics are expanding globally, offering fast-acting antidepressant relief through intranasal and IV formulations.

In parallel, governments in North America and Europe are revising drug policies-accelerating decriminalization and compassionate-use frameworks. Venture capital and biopharma companies are investing heavily in drug-delivery innovation, synthetic analogs, and controlled micro-dosing protocols, signaling a long-term structural market transformation.

Market Segmentation
By Drug Type: Psilocybin, Lysergic Acid Diethylamide (LSD), Ketamine, MDMA (Ecstasy), DMT, Others

By Application: Major Depressive Disorder, Post-Traumatic Stress Disorder (PTSD), Anxiety, Addiction, Cluster Headaches, Others

By End User: Hospitals, Specialty Clinics, Research Institutes, Home-Based Therapy Platforms

By Region: North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Recent Developments
• COMPASS Pathways reported successful Phase III psilocybin-therapy results for treatment-resistant depression in 2025.
• MAPS PBC completed regulatory filing with the U.S. FDA for MDMA-assisted PTSD therapy approval.
• Cybin Inc. advanced its CYB003 deuterated psilocybin analog into late-stage trials for major depressive disorder.
• Atai Life Sciences acquired digital-therapeutic firm Psyber to enhance AI-assisted mental-health interventions.
• Janssen Pharmaceuticals expanded global access for Spravato® (esketamine) nasal spray under controlled-use programs.

Expert Insight
"The psychedelic-drug renaissance is uniting neuroscience, psychotherapy, and digital health. As controlled access widens, these molecules could redefine the global standard of care for mental illness,"
- Lead Analyst, Exactitude Consultancy

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=48114

Market Drivers
• Mental-Health Epidemic: Rising global depression and anxiety rates demanding novel therapeutics.
• Regulatory Breakthroughs: Fast-track designations by FDA, EMA, and Health Canada for psychedelic-assisted therapies.
• R&D and Investment: Over USD 1.5 billion in venture and institutional funding since 2022.
• Cultural Acceptance: Growing mainstream and medical-community endorsement of controlled psychedelic use.

Forecast & Regional Insights
North America dominates with over 55% share (2024) driven by clinical trials, policy reform, and biotech investment hubs in the U.S. and Canada. Europe follows with rapid progress in the UK, Germany, and the Netherlands, where psychedelic therapy centers are emerging. The Asia-Pacific region is expected to witness the fastest CAGR of 10.9%, supported by growing research in Australia and government-backed mental-health initiatives in Japan and South Korea.

Conclusion
The Psychedelic Drugs Market is transitioning from fringe science to mainstream medicine. With data-driven clinical validation, scalable delivery models, and expanding public acceptance, psychedelics are set to redefine neuropsychiatric care and the economics of global mental health.

This report is also available in the following languages : Japanese (幻覚剤), Korean (환각제), Chinese (迷幻药), French (Drogues psychédéliques), German (Psychedelische Drogen), and Italian (droghe psichedeliche), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/48114/psychedelic-drugs-market#request-a-sample

Related Reports

Mental Health Psychedelic Apps Market
https://exactitudeconsultancy.com/reports/44951/mental-health-psychedelic-apps-market

Adult T-Cell Leukemia Lymphoma Treatment Market
https://exactitudeconsultancy.com/reports/75868/adult-t-cell-leukemia-lymphoma-treatment-market

Gout Therapeutics Market
https://exactitudeconsultancy.com/reports/75888/gout-therapeutics-market

Acute Radiation Syndrome Market
https://exactitudeconsultancy.com/reports/76062/acute-radiation-syndrome-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.